Overview

Location [1]
10q11.22
Protein [2]
Nuclear receptor coactivator 4
Synonyms [1]
ARA70, ELE1, PTC3, RFG

NCOA4 is altered in 0.09% of all cancers with thyroid gland papillary carcinoma, lung adenocarcinoma, breast invasive ductal carcinoma, colon adenocarcinoma, and adenocarcinoma of unknown primary having the greatest prevalence of alterations [3].

NCOA4 GENIE Cases - Top Diseases

The most common alterations in NCOA4 are NCOA4-RET Fusion (0.06%), NCOA4 A227V (0.39%), NCOA4 C426Y (0.85%), NCOA4 E436D (0.39%), and NCOA4 E485Q (0.20%) [3].

NCOA4 GENIE Cases - Top Alterations

Significance of NCOA4 in Diseases

Thyroid Gland Papillary Carcinoma +

Malignant Solid Tumor +

Histiocytosis +

Lymphoma +

Poorly Differentiated Thyroid Gland Carcinoma +

Thyroid Gland Medullary Carcinoma +

Thyroid Gland Undifferentiated (Anaplastic) Carcinoma +

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.